Re
Remix Ther
Cambridge MAFounded 202130 employees
Private CapbiotechPrivateGenetic Medicine
Platform: RNA Editing
Market Cap
N/A
All Drugs
3
Clinical Trials
5
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| REM-8705 | REM-8705 | Preclinical | 2 | GLP-1R | ACCALL | ||
| Olpacilimab | REM-4427 | Phase 1 | 1 | RET | Urothelial CaSLE | ||
| Ribotuximab | REM-8288 | Phase 1 | 2 | MALT1 | WMCSU |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (5)